×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ALLK

Allakos Stock Forecast, Price & News

$3.02
-0.11 (-3.51%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.92
$3.23
50-Day Range
$2.60
$4.30
52-Week Range
$2.54
$11.73
Volume
651,723 shs
Average Volume
1.46 million shs
Market Capitalization
$165.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.42

Allakos Stock Forecast (MarketRank)

Analyst Rating
Hold
2.10 Rating Score
Upside/​Downside
2,165.6% Upside
$68.42 Price Target
Short Interest
Healthy
12.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
1.01mentions of Allakos in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.68) to ($3.18) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.45 out of 5 stars

Medical Sector

107th out of 1,428 stocks

Pharmaceutical Preparations Industry

39th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Allakos logo

About Allakos (NASDAQ:ALLK)

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

ALLK Stock News Headlines

What 4 Analyst Ratings Have To Say About Allakos
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Company Calendar

Last Earnings
5/06/2022
Today
7/02/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$68.42
High Stock Price Forecast
$155.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+2,165.6%
Consensus Rating
Hold
Rating Score (0-4)
2.1
Research Coverage
10 Analysts

Profitability

Net Income
$-269.86 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.20 per share

Miscellaneous

Free Float
36,564,000
Market Cap
$165.43 million
Optionable
Not Optionable
Beta
0.98














Allakos Frequently Asked Questions

Should I buy or sell Allakos stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Allakos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View analyst ratings for Allakos
or view top-rated stocks.

What is Allakos' stock price forecast for 2022?

10 brokerages have issued 12-month target prices for Allakos' shares. Their ALLK stock forecasts range from $13.00 to $155.00. On average, they anticipate Allakos' share price to reach $68.42 in the next twelve months. This suggests a possible upside of 2,165.6% from the stock's current price.
View analysts' price targets for Allakos
or view top-rated stocks among Wall Street analysts.

How has Allakos' stock price performed in 2022?

Allakos' stock was trading at $9.79 at the beginning of 2022. Since then, ALLK stock has decreased by 69.2% and is now trading at $3.02.
View the best growth stocks for 2022 here
.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Allakos
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its earnings results on Friday, May, 6th. The company reported ($3.60) EPS for the quarter, missing the consensus estimate of ($1.71) by $1.89.
View Allakos' earnings history
.

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Dr. Robert Alexander Ph.D., CEO & Director (Age 52, Pay $1.39M)
  • Dr. Adam L. Tomasi Ph.D., Pres & COO (Age 52, Pay $1.06M)
  • Mr. Baird Radford III, Chief Financial Officer
  • Mr. Mark Asbury J.D., Exec. Officer (Age 59, Pay $701.69k)
  • Dr. Ruby Casareno Ph.D., Sr. VP of Technical Operations
  • Meg Fitzgerald, Sr. VP, Gen. Counsel, Sec. and Chief Compliance Officer
  • Dr. Sally D. Bolmer, Sr. VP of Regulatory Affairs & Drug Devel.
  • Dr. Henrik Sandvad Rasmussen, Strategic Advisor (Age 63)
  • Dr. Craig Paterson M.D., Chief Medical Officer
  • Brad Youngblood, Head of Research

What other stocks do shareholders of Allakos own?

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $3.02.

How much money does Allakos make?

Allakos (NASDAQ:ALLK) has a market capitalization of $165.43 million. The company earns $-269.86 million in net income (profit) each year or ($7.56) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 192 workers across the globe.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for Allakos is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.